EGFR amplification

News alerts, weekly reports and conference planners

Entrez ID:

1956

Related biomarkers:

‹

›

EGFR amplification	Non Small Cell Lung Cancer	EGFR amplification	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR amplification	Squamous Cell Carcinoma of Head and Neck	EGFR amplification	Squamous Cell Carcinoma of Head and Neck	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR amplification	Non Small Cell Lung Cancer	EGFR amplification	Non Small Cell Lung Cancer	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2
EGFR amplification	Glioblastoma	EGFR amplification	Glioblastoma	ABT-414 Sensitive: C2 – Inclusion Criteria ABT-414 Sensitive : C2	ABT-414 Sensitive: C2 – Inclusion Criteria ABT-414 Sensitive : C2
EGFR amplification	Glioblastoma	EGFR amplification	Glioblastoma	lapatinib Sensitive: C2 – Inclusion Criteria lapatinib Sensitive : C2	lapatinib Sensitive: C2 – Inclusion Criteria lapatinib Sensitive : C2
EGFR amplification	Esophageal Squamous Cell Carcinoma	EGFR amplification	Esophageal Squamous Cell Carcinoma	afatinib Sensitive: C2 – Inclusion Criteria afatinib Sensitive : C2	afatinib Sensitive: C2 – Inclusion Criteria afatinib Sensitive : C2
EGFR amplification	Glioblastoma	EGFR amplification	Glioblastoma	KD019 Sensitive: C2 – Inclusion Criteria KD019 Sensitive : C2	KD019 Sensitive: C2 – Inclusion Criteria KD019 Sensitive : C2
EGFR amplification	Glioma	EGFR amplification	Glioma	ABT-414 Sensitive: C2 – Inclusion Criteria ABT-414 Sensitive : C2	ABT-414 Sensitive: C2 – Inclusion Criteria ABT-414 Sensitive : C2
EGFR amplification	Glioblastoma	EGFR amplification	Glioblastoma	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2
EGFR amplification	Squamous Cell Carcinoma of Head and Neck	EGFR amplification	Squamous Cell Carcinoma of Head and Neck	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
EGFR amplification	Gastric Cancer	EGFR amplification	Gastric Cancer	cetuximab Sensitive: C3 – Early Trials cetuximab Sensitive : C3	cetuximab Sensitive: C3 – Early Trials cetuximab Sensitive : C3
EGFR amplification	Glioblastoma	EGFR amplification	Glioblastoma	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3
EGFR amplification	Melanoma	EGFR amplification	Melanoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
EGFR amplification	Mucosal Melanoma	EGFR amplification	Mucosal Melanoma	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3
EGFR amplification	Mucosal Melanoma	EGFR amplification	Mucosal Melanoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
EGFR amplification	Mucosal Melanoma	EGFR amplification	Mucosal Melanoma	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3
EGFR amplification	Mucosal Melanoma	EGFR amplification	Mucosal Melanoma	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
EGFR amplification	Colorectal Cancer	EGFR amplification	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
EGFR amplification	Colorectal Cancer	EGFR amplification	Colorectal Cancer	panitumumab Sensitive: C3 – Early Trials panitumumab Sensitive : C3	panitumumab Sensitive: C3 – Early Trials panitumumab Sensitive : C3
EGFR amplification	Non Small Cell Lung Cancer	EGFR amplification	Non Small Cell Lung Cancer	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3
EGFR amplification	Solid Tumor	EGFR amplification	Solid Tumor	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
EGFR amplification	Lung Cancer	EGFR amplification	Lung Cancer	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3
EGFR amplification	Lung Cancer	EGFR amplification	Lung Cancer	icotinib Resistant: C3 – Early Trials icotinib Resistant : C3	icotinib Resistant: C3 – Early Trials icotinib Resistant : C3
EGFR amplification	Non Small Cell Lung Cancer	EGFR amplification	Non Small Cell Lung Cancer	bevacizumab + erlotinib Sensitive: C3 – Early Trials bevacizumab + erlotinib Sensitive : C3	bevacizumab + erlotinib Sensitive: C3 – Early Trials bevacizumab + erlotinib Sensitive : C3
EGFR amplification	Non Small Cell Lung Cancer	EGFR amplification	Non Small Cell Lung Cancer	bevacizumab + gefitinib Sensitive: C3 – Early Trials bevacizumab + gefitinib Sensitive : C3	bevacizumab + gefitinib Sensitive: C3 – Early Trials bevacizumab + gefitinib Sensitive : C3
EGFR amplification	Squamous Cell Carcinoma of Head and Neck	EGFR amplification	Squamous Cell Carcinoma of Head and Neck	pembrolizumab + afatinib Sensitive: C3 – Early Trials pembrolizumab + afatinib Sensitive : C3	pembrolizumab + afatinib Sensitive: C3 – Early Trials pembrolizumab + afatinib Sensitive : C3
EGFR amplification	Gastric Cancer	EGFR amplification	Gastric Cancer	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
EGFR amplification	Esophageal Cancer	EGFR amplification	Esophageal Cancer	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
EGFR amplification	Non Small Cell Lung Cancer	EGFR amplification	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3
EGFR amplification	Esophageal Squamous Cell Carcinoma	EGFR amplification	Esophageal Squamous Cell Carcinoma	Z650 Sensitive: C3 – Early Trials Z650 Sensitive : C3	Z650 Sensitive: C3 – Early Trials Z650 Sensitive : C3
EGFR amplification	Non Small Cell Lung Cancer	EGFR amplification	Non Small Cell Lung Cancer	afatinib Resistant: C3 – Early Trials afatinib Resistant : C3	afatinib Resistant: C3 – Early Trials afatinib Resistant : C3
EGFR amplification	Glioblastoma	EGFR amplification	Glioblastoma	nivolumab + bevacizumab Resistant: C3 – Early Trials nivolumab + bevacizumab Resistant : C3	nivolumab + bevacizumab Resistant: C3 – Early Trials nivolumab + bevacizumab Resistant : C3

EGFR amplification

Associations